FDG PET and Lymphoma

When treating a pervasive cancer like lymphoma, it’s crucial that clinicians and oncologists get the most complete picture of the cancer’s spread within the body as possible.

Fluorodeoxyglucose-positron emission tomography (FDG-PET) is one way of doing this. An imaging technique similar to MRI, FDG-PET can isolate residual cancer cells after treatment and identify whether additional treatment is needed.

Description and Significance

Fluorodeoxyglucose, or FDG, is a sugar-like substance derived from basic glucose. It is injected in the body, where it is absorbed most easily by cancerous cells. This is because such rapidly dividing cells require a steady supply of glucose. Using positron-detecting camera equipment, doctors can then detect the energy given off by that much FDG, mapping their locations onto a 3D representation of the body.

A CT scan is usually conducted concurrently to provide more definitive results. Used in conjunction, FDG-PET and CT can isolate discrete tumors, metastasized cancer cells, and lymph node involvement. Because a physical examination and blood work from only one or several involved lymph nodes cannot paint a comprehensive picture of the spread of the lymphoma throughout the body, doctors depend on FDG-PET and lymphoma tests to provide a full-body analysis for diagnostic, staging, and prognostic purposes.

Side Effects

As a non-invasive procedure, there are no side effects to a FDG-PET scan. The FDG can alter blood chemistry slightly, but this quickly returns to normal. The entire process was developed to mitigate the need for more invasive and time-consuming methods of detecting extranodal cancer involvement.

Administration

You will be asked to fast the night before a FDG-PET test in order to settle your blood glucose levels. A blood glucose test is taken immediately prior to the FDG-PET test to calibrate the findings. You will be asked to rest for an hour after receiving the injection of FDG to allow the compound to be absorbed by any potential tumors. You will then be placed in a machine not unlike a CT scanner (indeed, this is the time any CT scans will also be done), and subjected to the PET scan. This should take about 45 minutes, after which you are free to go.

Your oncologist will analyze the data and then schedule a time for you to come in and discuss any unusual findings. The 3D image that FDG-PET for lymphoma produces can detect even tiny pockets of cancer cells that may have survived treatment, and tests administered during chemotherapy or radiotherapy can help direct treatment to more effectively address each individual case.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap